What insurance policy changes affect HCPCS C9309?

There are 15 tracked policy changes affecting HCPCS C9309, including updates from Kansas Medicaid (KanCare), Health Net, Blue Cross Blue Shield of Rhode Island. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS C9309?

Payers that have issued tracked updates for HCPCS C9309 include: Kansas Medicaid (KanCare), Health Net, Blue Cross Blue Shield of Rhode Island, BCBS Michigan, Texas Medicaid, Blue Cross & Blue Shield of Mississippi, Harvard Pilgrim Health Care, Blue Cross Blue Shield of North Dakota.

How do I get notified when HCPCS C9309 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS C9309. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS C9309?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

C9309 — Injection, onasemnogene abeparvovec-brve, per treatment: Insurance Policy Changes

C9309 Insurance Policy Changes

HCPCS C9309 is officially defined as "Injection, onasemnogene abeparvovec-brve, per treatment." HCPCS C9309 is referenced in 15 tracked payer policy changes from Kansas Medicaid (KanCare), Health Net, and 6 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS C9309 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Medium impact

Point32Health medical drug program updates

Harvard Pilgrim Health Care·Effective May 1, 2026

Point32Health updated prior authorization requirements for three medical drugs: Itvisma now requires prior auth for Tufts Health Together members, Yescarta eligibility expanded for CNS lymphoma patients, and Encelto now requires retina specialist administration. These changes affect oncology and ophthalmology specialties with specific effective dates in May 2026.

C9309 Insurance Policy Changes

KMAP BULLETIN: HCPCS Codes Updates – July 2026

26-629 Updates to Prior Authorization Requirements

26-630 Updates to Prior Authorization Requirements

Additional HCPCS Level II Code Changes and Modifier Changes

HCPCS 1st-quarter update: New, deleted codes

First Quarter 2026 HCPCS Updates for Texas Medicaid

First Quarter 2026 HCPCS Updates for the CSHCN Services Program

State and School Employees' Health Insurance Plan - Itvisma (onasemnogene abeparvovec-brve)

Itvisma (onasemnogene abeparvovec-brve)

Point32Health medical drug program updates

KMAP BULLETIN: HCPCS Codes Update – April 2026

26-628 Updates to Prior Authorization Requirements

26-631 Updates to Prior Authorization Requirements

Pharmacy Policies Updates

HCPCS replacement codes established, effective April 1, 2026